Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
Avalo Therapeutics Chief Medical Officer Mittie Doyle reported an exercise-and-sell transaction in Avalo Therapeutics, Inc. common stock. On June 30, 2026, Doyle sold 4,654 shares in an open-market sale at $20.00 per share, while also exercising options to acquire a total of 4,654 shares of common stock at strike prices of $8.04 and $12.65 per share. The options exercised relate to grants that vest over four years, and all transactions were carried out under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating the trades were pre‑scheduled rather than discretionary market timing.
Avalo Therapeutics director Philip Ron M reported a grant of stock options covering 69 shares of common stock. The options were awarded on June 30, 2026 as a compensation grant, with an exercise price of $18.48 per share, are 100% vested, and expire on June 30, 2036.
Avalo Therapeutics director Kevin Robert Lind received a new stock option grant. On June 30, 2026, he was awarded options covering 1,105 shares of Avalo common stock at an exercise price of $18.48 per share. The options are 100% vested at grant and expire on June 30, 2036, leaving him with 1,105 options outstanding after this transaction.
Avalo Therapeutics director Rita Jain received a stock option grant as part of her compensation. On June 30, 2026, she was awarded options covering 1,080 shares of Avalo Therapeutics common stock at an exercise price of $18.48 per share. These options are fully vested and expire on June 30, 2036. Following this grant, she directly holds options on 1,080 underlying shares.
Avalo Therapeutics Chief Medical Officer Doyle Mittie reported an exercise-and-sell transaction in company stock. On June 23, 2026, Mittie exercised options to acquire 1,450 shares of Common Stock at $8.04 per share and sold 1,450 shares at $18.00 per share in an open-market sale. Following these transactions, Mittie directly holds 51,776 Common shares and 116,871 stock options. The filing notes that these trades were made under a Rule 10b5-1 trading plan adopted on November 13, 2025, indicating they were pre-scheduled rather than timed discretionarily.
Avalo Therapeutics director Philip Ron received a grant of stock options covering 40,200 shares of common stock at an exercise price of $17.83 per share. The options vest in three substantially equal annual installments on the first, second and third anniversaries of the June 23, 2026 grant date, contingent on continued board service. Following this award, his reported option holdings from this filing total 40,200 derivative securities.
Avalo Therapeutics, Inc. director Philip Ron M has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This document establishes his status as a director and serves as the baseline disclosure of his equity position in Avalo shares and related securities.
Avalo Therapeutics appointed Ron Philip to its board of directors effective June 23, 2026. He will serve until the 2027 annual meeting and join the Compensation Committee and the Science, Development and Commercial Advisory Committee.
Under the company’s non-employee director compensation plan, Philip will receive a non-qualified stock option to purchase 40,200 shares of common stock, granted June 23, 2026, vesting in three equal annual installments subject to continued service. The exercise price equals the closing price of Avalo’s stock on that grant date. The board determined he is independent under Nasdaq rules, and he will sign the company’s standard indemnification agreement.
Avalo Therapeutics, Inc. reported a joint Schedule 13G showing beneficial ownership of 5,721,109 shares of common stock by Commodore Capital-related filers as of June 11, 2026.
That position is presented as 9.9% of the class, calculated using 52,565,572 shares outstanding as of May 8, 2026. The 5,721,109 figure is composed of 1,018,319 shares, 1,400,000 shares issuable upon exercise of pre-funded warrants, and 3,302,790 shares underlying Series C-1 Non-Voting Convertible Preferred Stock, each subject to a 9.99% Beneficial Ownership Limitation.
Avalo Therapeutics reported pipeline progress and updated investor materials. The company is advancing AVTX-010, a long-acting next‑generation anti‑IL‑1β antibody, with an Investigational New Drug application planned for the first half of 2027. AVTX-010 is intended for hidradenitis suppurativa (HS) and other inflammatory diseases.
Avalo highlighted abdakibart, its lead anti‑IL‑1β antibody, which produced a 42.5% HiSCR75 response at week 16 in the Phase 2 LOTUS HS trial, versus 25.6% on placebo, and a 61.7% HiSCR50 response versus 40.7%. Safety was described as favorable, with treatment‑emergent adverse event rates similar to placebo.
The investor presentation notes an HS therapeutics market projected above $10B by 2035 and describes Avalo as capitalized to fund operations into 2029, supported by approximately $479M in cash, cash equivalents and investments as of May 31, 2026.